AI医疗商业化有望加速 QDII基金积极重仓布局

Core Viewpoint - The AI healthcare sector is in a nurturing phase, with increasing interest from public funds, particularly in overseas expansion as a key growth driver for companies in this field [1][2][6]. Group 1: Investment Trends - Public funds are heavily investing in AI healthcare companies, with a focus on those expanding internationally, such as JingTai Holdings and YiDu Technology, which are seeing significant revenue growth from overseas markets [2][3]. - Companies like Mirxes have reported that approximately 70% of their revenue comes from international markets, indicating a strong reliance on overseas expansion for growth [3]. Group 2: Valuation Concerns - Despite the growth potential, many AI healthcare companies are facing high valuations, with some trading at sales multiples of tens or even hundreds, raising concerns about sustainability [4][5]. - For instance, Mirxes has a market capitalization exceeding HKD 17 billion, which is notably higher than its competitors like Grail, despite Grail having significantly larger revenue [4]. Group 3: Future Outlook - Fund managers believe that the current high valuations are linked to the varying stages of commercialization among companies, with U.S. firms having a head start in the market [6][8]. - The AI healthcare sector is expected to see accelerated growth in the coming years, particularly in areas like brain-computer interfaces, which are projected to transition from laboratory to clinical applications within 1-2 years [8].